Part IV — Neuropeptides and Social Peptides

Chapters 20–24

Your brain runs on peptides. Not exclusively — the fast signaling is done by small molecules like glutamate and GABA — but the slow, modulatory, mood-and-motivation layer is largely peptidergic. There are somewhere over a hundred known neuropeptides, they act on timescales of seconds to hours rather than milliseconds, and they do not so much carry messages as change how other messages are interpreted.

That distinction is why Part IV is both the most fascinating part of this book and the most treacherous.

Why this part is where science communication goes to die

Neuropeptides produce headlines. "The love hormone." "The hunger hormone." "Your body's natural morphine." Every one of those phrases is built on something real, and every one of them is wrong in the specific way that does the most damage: it takes a molecule with context-dependent, population-dependent, dose-dependent effects and compresses it into a single noun.

Oxytocin is the worst offender and the best teacher. It is genuinely involved in labor, in breastfeeding, in pair bonding, in trust. It is also, in careful experimental work, associated with increased favoritism toward one's own group and, in some settings, increased hostility toward outsiders. It is not a love hormone. It is a social salience modulator whose effects depend heavily on who is in the room. And when researchers gave it to humans intranasally and looked for clinical benefit in autism, in social anxiety, in PTSD, the results were largely disappointing — a fact that almost never accompanies the nickname.

Part IV is where you learn to distrust a good headline about your own brain.

The five chapters

Chapter 20 — Endorphins, Enkephalins, and the Opioid Peptides starts with one of the most satisfying facts in pharmacology: morphine works because it happens to resemble molecules your body already makes. Not the other way around. The chapter covers the three opioid peptide families, their three receptor types and very different jobs, pain modulation, the runner's high (where the evidence is more interesting than the story), and one of medicine's most elegant experiments — the demonstration that placebo pain relief can be blocked by an opioid antagonist.

Chapter 21 — Oxytocin and Vasopressin takes two nine-amino-acid peptides that differ at two positions and produce dramatically different physiology. It covers the uncontroversial obstetric uses, the prairie vole work that built the bonding literature, the replication problems, the in-group/out-group findings, the genuine open question of whether intranasal delivery reaches the brain at all, and a clinical trial record that is much less encouraging than the popular account.

Chapter 22 — Neuropeptide Y, Substance P, and the Brain's Regulators contains what may be the single best cautionary tale in this book. Substance P was a beautifully characterized pain-and-mood peptide. Blocking its receptor was mechanistically perfect. The preclinical data was excellent. The antidepressant trials failed comprehensively. Meanwhile, CGRP — a related neuropeptide nobody was excited about — produced a genuinely transformative class of migraine drugs. Mechanism did not predict either outcome, and the chapter is honest about how little anyone saw coming.

Chapter 23 — Nootropic and Neuroprotective Peptides is a chapter about reading evidence from another regulatory culture. Semax and Selank are approved in their home jurisdiction and essentially unknown in Western clinical practice; the literature exists but is hard to access and was produced under different standards. The chapter neither dismisses that literature nor accepts it, and models what careful engagement with hard-to-evaluate evidence looks like. It also addresses why cognitive enhancement claims are unusually easy to fool yourself about.

Chapter 24 — PT-141 and the Sexual Function Peptides tells one of pharmacology's better accidents: a tanning-peptide program that noticed an unexpected side effect and followed it to an FDA approval. The chapter covers what an approval for a narrow population does and does not license, the difference between a drug that affects desire and one that affects blood flow, and the unapproved tanning peptides that came out of the same research line with a genuine melanoma concern.

The barrier that shapes everything

One physical fact governs this entire part: the blood-brain barrier.

Most peptides cannot cross it. This is excellent design — you do not want circulating gut hormones freely rearranging your cortex — and it is catastrophic for drug development. A neuropeptide with a perfect mechanism and no route into the brain is not a drug candidate; it is a research tool.

Nearly every failure in Part IV traces back to that barrier, or to the closely related problem that the brain's peptide systems are so heavily interconnected that pushing on one displaces three others. The successes — the orexin antagonists for insomnia, the CGRP antibodies for migraine — largely worked by finding targets that were either accessible from outside the brain or unusually isolated.

📋 Your Evidence Dossier — Part IV

Chapter 21 teaches the field's most underused rating skill: what to do when the honest answer is "it depends on context." A molecule whose effect reverses depending on who is in the room does not get a single rating; it gets a rating per context, or it gets a plain statement that the question is not yet well-posed.

Chapter 22 adds the discipline of crossing the blood-brain barrier in Field 3 — because for any neuropeptide claim, "how does it get there?" is the question that settles most arguments before they start.

Chapters in This Part